IASLC World Conference on Lung Cancer

William N. William Jr, MD, discusses the design, toxicity lessons, and TP53 co-mutant signal from the phase 2 AMIGO-1 trial of amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.

Julia K. Rotow, MD, discusses why dual EGFR inhibition prevented acquired resistance mutations but did not extend PFS, and where the combination fits now.

Laura Alder, MD, discusses a retrospective analysis in which early-morning tarlatamab infusions during cycle 1 did not improve outcomes in small cell lung cancer, and what a prospective test would require.

Laura Alder, MD, discusses a multi-institutional real-world analysis of local consolidation and continued tarlatamab in patients with oligoprogressive small cell lung cancer.

Julia K. Rotow, MD, discusses how T-DXd, zongertinib, and sevabertinib may be sequenced in first-line HER2-mutant NSCLC and why resistance profiling at progression matters.

Julia K. Rotow, MD, discusses subgroup results and post-progression treatment imbalances in the phase 3 DESTINY-Lung04 trial of first-line T-DXd in HER2-mutant NSCLC.

Yuanyuan Zhao, MD, discusses phase 1b data for the PD-1/VEGF bispecific RC148 (ABBV-1480) plus chemotherapy in first-line NSCLC, how it is engineered differently from ivonescimab and pumitamig, and what the global phase 3 program needs to show.

Alexander Drilon, MD, discusses future directions for zidesamtinib in TKI-naive, ROS1-positive NSCLC following the ARROS-1 trial.

Alexander Drilon, MD, discusses phase 1/2 ARROS-1 efficacy and safety findings with zidesamtinib in TKI-naive, ROS1-positive NSCLC.

Jay M. Lee, MD, discusses how NAUTIKA1 compares with ALNEO and LORIN, why full genomic profiling is now essential before starting chemoimmunotherapy, and how tumor boards will manage early-stage NSCLC in 5 years.

Jay M. Lee, MD, discusses the primary analysis of the ALK+ cohort of NAUTIKA1, what MPR status adds to risk stratification, and whether neoadjuvant alectinib is ready for patients today.

David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.

David R. Gandara, MD, discusses why KRAS G12C predicted outsized benefit with first-line cemiplimab in PD-L1–high NSCLC and what it means for trial design.

The final OS analysis of PAPILLON did not reach statistical significance in the ITT population, but a pre-specified crossover-adjusted analysis showed a 43% reduction in the risk of death.

An exploratory landmark analysis of the phase 3 ADAURA trial showed 8-year OS rates of 79% versuss 64% with placebo, with benefit maintained across stages and subgroups.

Frontline zidesamtinib produced a 94% response rate and 100% intracranial response rate in TKI-naive ROS1-positive advanced NSCLC.

First-line trastuzumab deruxtecan reduced the risk of progression or death by 37% compared with pembrolizumab plus chemotherapy in HER2-mutant non–small cell lung cancer.

Luis E. Raez, MD, discusses how oral TKIs may shift frontline sequencing across ROS1-positive, HER2-mutant, and EGFR exon 20 insertion–positive NSCLC.

Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.

Rajwanth R. Veluswamy, MD, MSCR, discusses universal KRAS testing, the frontline immunotherapy signal in KRAS G12C+ NSCLC, and next-generation G12C inhibitors.

Luis E. Raez, MD, discusses molecular testing, screening gaps, and global drug access challenges in lung cancer across Latin America and the US.

Adding intercalated gefitinib to adjuvant chemotherapy improved DFS vs chemotherapy alone in completely resected stage II-IIIB EGFR-mutant NSCLC in a phase 3 trial.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses phase 1 dose-optimization data supporting the 2.5 mg/kg dose of iza-bren in EGFR-mutated NSCLC.

A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.

Primary results from the phase 3 ARTEMIS-008 trial presented at WCLC 2026 showed risvutatug rezetecan reduced the risk of death by 54% and more than doubled PFS.

Tambotatug pelitecan improved survival and confirmed ORR in the phase 3 TAISHAN-302 trial presented at WCLC 2026.